Key result
CMR phenotyping emerges as the preferred standard for primary prevention ICD decisions in cardiac sarcoidosis.
Observational analysis shows enhanced decision-making for implantable cardioverter-defibrillator in cardiac sarcoidosis, implying improved patient outcomes.
Journal Article Cardiovascular magnetic resonance phenotyping: the new standard for primary prevention implantable cardioverter-defibrillator decision-making in cardiac sarcoidosis Get access Harold Mathijssen, Harold Mathijssen Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Parag H Bawaskar, Parag H Bawaskar Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Chetan Shenoy Chetan Shenoy Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA Corresponding author. Tel: (612) 626 1391, Email: [email protected] https://orcid.org/0000-0001-8877-4999 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehaf759, https://doi.org/10.1093/eurheartj/ehaf759 Published: 25 September 2025
No takes yet. Share an insight, caveat, or question.
Mathijssen et al. (2025) conducted an editorial in cardiac sarcoidosis. Cardiovascular magnetic resonance phenotyping was evaluated. Cardiovascular magnetic resonance phenotyping is discussed as the new standard for primary prevention implantable cardioverter-defibrillator decision-making in cardiac sarcoidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: